Mesoblast Limited SEC filings document its foreign-issuer reporting through Form 6-K submissions that incorporate Australian Securities Exchange announcements, Appendix 4C activity reports, press releases, and R&D presentation materials. The disclosures cover Ryoncil® commercialization, operating cash activity, and clinical programs built around allogeneic mesenchymal lineage stromal cell products.
The filing record also includes ASX notices for director interests, cessation of securities, unquoted equity securities, and applications for quotation of securities. These materials describe capital-structure changes, governance reporting, product and platform updates, and the company’s Form 20-F foreign private issuer framework.
Mesoblast Limited furnished a Form 6-K summarizing Australian Securities Exchange disclosures about director equity awards and other unquoted securities. The filing attaches Appendix 3Y notices showing option grants, with no cash consideration, to multiple directors following shareholder approval at the 2025 annual general meeting.
Chief Executive Officer Dr Silviu Itescu received 2,025,600 new options, increasing his option holdings to 18,475,158 while his 78,958,928 ordinary shares were unchanged. Director Dr Eric Rose received 820,000 options, bringing his total to 6,413,451 options with 6,749,274 ordinary shares unchanged. Director Gregory George received 200,000 options to acquire ordinary shares under the employee share option plan. Director Lyn Cobley received 200,000 options, adding to her existing direct and indirect shareholdings. The 6-K also forwards an Appendix 3G notice on unquoted equity securities.
Mesoblast Limited furnished a Form 6-K summarizing Australian Securities Exchange disclosures about director equity awards and other unquoted securities. The filing attaches Appendix 3Y notices showing option grants, with no cash consideration, to multiple directors following shareholder approval at the 2025 annual general meeting.
Chief Executive Officer Dr Silviu Itescu received 2,025,600 new options, increasing his option holdings to 18,475,158 while his 78,958,928 ordinary shares were unchanged. Director Dr Eric Rose received 820,000 options, bringing his total to 6,413,451 options with 6,749,274 ordinary shares unchanged. Director Gregory George received 200,000 options to acquire ordinary shares under the employee share option plan. Director Lyn Cobley received 200,000 options, adding to her existing direct and indirect shareholdings. The 6-K also forwards an Appendix 3G notice on unquoted equity securities.
Mesoblast Ltd director Philip R. Krause has filed an initial ownership report showing his equity position in the company. He directly holds 287,500 Ordinary Shares, which are represented by American Depositary Shares. In addition, he holds multiple option awards over Ordinary Shares with exercise prices between $0.32 and $0.99 per share and expirations ranging from 2029 to 2031. Footnotes indicate that certain options were granted in 2023 and 2024 and are scheduled to vest between October 24, 2026 and August 27, 2027, aligning his compensation with the company’s long-term performance.
Mesoblast Ltd director Philip R. Krause has filed an initial ownership report showing his equity position in the company. He directly holds 287,500 Ordinary Shares, which are represented by American Depositary Shares. In addition, he holds multiple option awards over Ordinary Shares with exercise prices between $0.32 and $0.99 per share and expirations ranging from 2029 to 2031. Footnotes indicate that certain options were granted in 2023 and 2024 and are scheduled to vest between October 24, 2026 and August 27, 2027, aligning his compensation with the company’s long-term performance.
Mesoblast Ltd director Philip James Facchina filed an initial Form 3, disclosing his existing equity-linked interests in the company. He reports multiple options (rights to buy Ordinary Shares) with exercise prices of $2.26, $0.36, and $0.97 per share and expirations between 2028 and 2031. He also reports warrants and Ordinary Shares held indirectly through HNP, LLC, a company in which he is a member. The footnotes state that the Ordinary Shares are represented by American Depositary Shares.
Mesoblast Ltd director Jane Catherine Bell has filed an initial Form 3 reporting her equity interests in the company. The filing lists multiple options to buy Ordinary Shares, including options over 108,910 shares at an exercise price of 0.3600 per share expiring on 2030-10-11, and options over 64,103 shares at an exercise price of 0.9700 per share expiring on 2031-08-26. It also reports indirect ownership of 622,492 Ordinary Shares held by Ms. Bell and Geoffrey Arthur Bell as trustees for Ms. Bell's self-managed superannuation fund.
Mesoblast Ltd filed a Form 3 identifying James Michael Obrien, Chief Financial Officer, as a reporting person for MESO. The filing lists no equity or derivative transactions and shows no buy, sell, acquire, dispose, or other activity in the summarized data.
Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company. He directly holds 6,034,554 Ordinary Shares and an additional 714,720 Ordinary Shares, which are represented by American Depositary Shares.
He also reports multiple option awards over Ordinary Shares, including 820,000 underlying shares at an exercise price of $2.46 per share expiring in 2032, and other grants at exercise prices of $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031. Several recent option grants vest only if Mr. Rose achieves specified milestones.
Mesoblast Limited has filed a Form 6-K highlighting plans for its inaugural R&D Day on April 8, 2026, in New York City. The event will run from 8:00am to 11:00am EST and be webcast live for global access.
Senior leadership and external experts will present on corporate strategy, commercialization of flagship product Ryoncil®, and multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. Mesoblast will also unveil new technology intended to support the next era of cellular medicines.
The disclosure reiterates that Mesoblast develops allogeneic cellular therapies for severe inflammatory conditions, including FDA-approved Ryoncil® for pediatric steroid-refractory acute graft versus host disease, and is advancing remestemcel-L and rexlemestrocel-L programs with global partnerships, extensive patents, and proprietary large-scale manufacturing.
Mesoblast Limited has filed a Form 6-K highlighting plans for its inaugural R&D Day on April 8, 2026, in New York City. The event will run from 8:00am to 11:00am EST and be webcast live for global access.
Senior leadership and external experts will present on corporate strategy, commercialization of flagship product Ryoncil®, and multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. Mesoblast will also unveil new technology intended to support the next era of cellular medicines.
The disclosure reiterates that Mesoblast develops allogeneic cellular therapies for severe inflammatory conditions, including FDA-approved Ryoncil® for pediatric steroid-refractory acute graft versus host disease, and is advancing remestemcel-L and rexlemestrocel-L programs with global partnerships, extensive patents, and proprietary large-scale manufacturing.
Mesoblast Ltd director George Gregory filed an initial Form 3 detailing his derivative holdings in MESO. The filing lists indirect warrants over 6,830,602 ordinary shares at an exercise price of $2.86 expiring in 2028, plus direct warrants over 200,000 ADS at $9.06 and 1,600,000 ordinary shares or ADS at $2.50 expiring between 2028 and 2029.
He also holds three option tranches over 66,667, 66,667 and 66,666 ordinary shares at $1.72 per share, which become exercisable between 2026 and 2028 and expire in 2032. The Form 3 reports these existing positions and does not show new purchases or sales.
Mesoblast Ltd director George Gregory filed an initial Form 3 detailing his derivative holdings in MESO. The filing lists indirect warrants over 6,830,602 ordinary shares at an exercise price of $2.86 expiring in 2028, plus direct warrants over 200,000 ADS at $9.06 and 1,600,000 ordinary shares or ADS at $2.50 expiring between 2028 and 2029.
He also holds three option tranches over 66,667, 66,667 and 66,666 ordinary shares at $1.72 per share, which become exercisable between 2026 and 2028 and expire in 2032. The Form 3 reports these existing positions and does not show new purchases or sales.
Mesoblast Limited reported a change in director Gregory George’s holdings following on-market purchases of its securities in early March 2026. Across 3–6 March 2026, he acquired 5,644,192 ordinary shares and 542,633 American Depositary Shares (ADS) for total consideration of US$16,370,330.90.
Each ADS represents a beneficial interest in 10 ordinary shares. George’s interests are held both directly and indirectly, including through JP Morgan Nominees Australia Pty Limited and G to the Fourth Investments, LLC, as well as ADSs where family members have granted him power of attorney.
After these transactions, his direct holdings remain at 5 ordinary shares, 12,829,328 ADSs, 200,000 warrants convertible into ADS, and 1,600,000 warrants to acquire ordinary shares. Indirectly, he now holds 5,644,192 ordinary shares, 14,415,410 ADSs, and 6,830,602 warrants to acquire ordinary shares.
Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.
Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.
Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.
Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.